ACADIA Pharmaceuticals

$54.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.88 (+1.63%) Today

$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell ACAD and other stocks, options, and ETFs commission-free!

About ACAD

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. The listed name for ACAD is ACADIA Pharmaceuticals Inc. Common Stock.

CEO

Stephen R. Davis

Employees

503

Headquarters

San Diego, California

Founded

1993

Market Cap

8.70B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.08M

High Today

$54.84

Low Today

$53.53

Open Price

$54.07

Volume

1.11M

52 Week High

$58.72

52 Week Low

$30.02

Collections

Research And Development

Analyst Ratings

94%

of 18 ratings

Buy

94%

Hold

Sell

ACAD Earnings

-$0.59

-$0.39

-$0.20

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 24, After Hours